Algert Global LLC Makes New $1.45 Million Investment in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Algert Global LLC purchased a new position in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 261,167 shares of the medical technology company's stock, valued at approximately $1,452,000. Algert Global LLC owned about 0.18% of Alphatec as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in ATEC. Net Worth Advisory Group purchased a new stake in shares of Alphatec during the third quarter valued at approximately $76,000. Comerica Bank boosted its stake in Alphatec by 64.8% during the 1st quarter. Comerica Bank now owns 6,443 shares of the medical technology company's stock valued at $89,000 after purchasing an additional 2,534 shares during the last quarter. Van ECK Associates Corp increased its holdings in shares of Alphatec by 57.0% in the 3rd quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company's stock worth $99,000 after purchasing an additional 6,998 shares in the last quarter. Tempus Wealth Planning LLC purchased a new position in shares of Alphatec in the third quarter worth $107,000. Finally, Atria Investments Inc boosted its position in shares of Alphatec by 8.0% during the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company's stock valued at $109,000 after buying an additional 1,460 shares during the last quarter. 66.35% of the stock is owned by institutional investors.

Alphatec Stock Performance

ATEC traded up $0.11 during midday trading on Friday, reaching $10.48. The company had a trading volume of 636,282 shares, compared to its average volume of 1,948,828. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $17.34. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The business has a 50-day moving average of $7.02 and a two-hundred day moving average of $8.22.

Wall Street Analysts Forecast Growth

ATEC has been the topic of several research analyst reports. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Alphatec in a research note on Thursday, October 31st. Stifel Nicolaus dropped their target price on shares of Alphatec from $19.00 to $16.00 and set a "buy" rating on the stock in a report on Thursday, August 1st. Morgan Stanley lowered shares of Alphatec from an "overweight" rating to an "equal weight" rating in a research note on Thursday, August 1st. Barclays raised their price target on Alphatec from $19.00 to $20.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 19th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $20.00 price objective on shares of Alphatec in a research report on Friday, August 30th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Alphatec currently has a consensus rating of "Moderate Buy" and an average price target of $17.11.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.